Evidence map›Paper›PMID 42627037›Full record

ArticleG3 (Bethesda, Md.)2026

Involvement of tumor suppressor candidate 3 in mouse survival, craniofacial, and cortical development.

Paul P R Iyyanar, Andrew Vontell, Ammar Husami, Ethan Sperry, K Nicole Weaver, Rolf W Stottmann

Abstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paul P R IyyanarSteve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, United States.ORCID 0000-0003-0327-5395
Andrew VontellSteve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, United States.
Ammar HusamiDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, United States.ORCID 0000-0002-4287-2857
Ethan SperryDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, United States.
K Nicole WeaverDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, United States.
Rolf W StottmannSteve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, United States.ORCID 0000-0003-4512-6806

Funding

Forward genetic analysis of congenital craniofacial malformationsR01DE027091 · NIDCR · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI STOTTMANN, ROLF W · 2019 to 2023
$2.9M
Abigail Wexner Research InstituteNationwide Children's HospitalNIDCR NIH HHS R01 DE027091NIH HHS R01DE027091
6 · The paper itself

Abstract

Tumor suppressor candidate 3 is an integral component of the oligosaccharyltransferase complex and is required for the N-glycosylation of proteins. While tumor suppressor candidate 3 has been implicated in cancer and autosomal recessive non-syndromic intellectual disability, some patients also exhibit distinct facial features. However, the role of Tusc3 in craniofacial development is unknown. Here, we report a patient presenting with cleft lip and palate who was found to carry a homozygous variant in the TUSC3 promoter region in addition to a maternally inherited chromosomal duplication. In order to evaluate a potential role for TUSC3 in craniofacial development, we analyzed Tusc3 deletion mouse mutants from the International Mouse Phenotyping Consortium (IMPC). Initial IMPC phenotyping data suggested that a subset of Tusc3 deletion mice could develop cleft palate, micrognathia, and aglossia. We further identified that Tusc3 is expressed in the craniofacial and brain regions during embryonic development. Upon characterizing the Tusc3 deletion line, we observed that most homozygous mutants exhibit preweaning lethality. While craniofacial defects occur at a very low frequency in the deletion mutants, we identified a modest reduction in cortical area. Furthermore, RNA-seq analysis surprisingly revealed that no other genes in the developing brain or face were significantly affected upon loss of Tusc3. These findings suggest that Tusc3 can contribute to congenital malformations in both craniofacial and cortical development.

Indexed as

Cerebral CortexCraniofacial AbnormalitiesMembrane ProteinsTumor Suppressor ProteinsAnimalsCleft PalateFemaleHomozygoteHumansMaleMicePhenotypeMembrane ProteinsTumor Suppressor ProteinsTUSC3 protein, humancleft palatecortexcraniofacialglycosylationmandibleRNA-seqTusc3

Identifiers

PMID42627037
PMCPMC13643766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.